Accordingly, compound 1g was found to inhibit TRKA (neurotrophic tyrosine receptor kinase 1, NTRK1), DYRK1A/1B (dual specificity tyrosine-phosphorylation-regulated kinase 1A and 1B), and CK1δ (casein kinase 1 delta, CSNK1D) kinases, reportedly associated with overexpression in cancer cells [11,37,38,39]. Here, DYRK1A is linked to cancer.